Acelyrin, Inc. (SLRN)

Market Cap	444.44M
Revenue (ttm)	n/a
Net Income (ttm)	-264.41M
Shares Out	100.33M
EPS (ttm)	-2.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,136
Open	4.720
Previous Close	4.720
Day's Range	4.430 - 4.840
52-Week Range	3.360 - 8.890
Beta	n/a
Analysts	Buy
Price Target	11.50 (+159.59%)
Earnings Date	Nov 13, 2024

About SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2023
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: SLRN
• Website: https://www.acelyrin.com

Analyst Forecast

According to 6 analysts, the average rating for SLRN stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 159.59% from the latest price.

Price Target

$11.5

(159.59% upside)

Analyst Consensus: Buy